-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Benzinga·01/30/2026 14:30:16
Listen to the news
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.